Regeneron Pharmaceuticals Inc (REGN : NASDAQ)
Common Stock
$930.67
USD
-42.69 (-4.39%)
Last updated: 2026-11-04
Follow REGN
REGN
Regeneron Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
-4.39%
1 Week
+14.44%
1 Month
+28.11%
YTD
+20.35%
Key Statistics
Market Cap
$100.69B
52W High
$991.73
52W Low
$590.83
P/E Ratio
21.52
50 Day MA
$795.85
200 Day MA
$738.63
Beta
0.10
Dividend Yield
0.38%
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/4/2026 | $989.90 | $991.73 | $927.42 | $930.67 | $930.67 | 1,383,075 |
| 11/3/2026 | $956.28 | $975.49 | $953.00 | $973.36 | $973.36 | 1,197,090 |
| 11/2/2026 | $927.22 | $974.00 | $927.00 | $961.26 | $961.26 | 1,656,718 |
| 10/30/2026 | $869.43 | $935.35 | $839.08 | $927.89 | $927.89 | 2,870,600 |
| 10/29/2026 | $826.14 | $828.19 | $811.63 | $818.77 | $818.77 | 780,811 |
| 10/28/2026 | $807.06 | $821.16 | $802.20 | $813.27 | $813.27 | 532,282 |
| 10/27/2026 | $807.67 | $816.14 | $804.17 | $816.10 | $816.10 | 716,874 |
| 10/26/2026 | $812.31 | $817.17 | $796.61 | $807.67 | $807.67 | 417,836 |
| 10/23/2026 | $819.09 | $819.09 | $801.22 | $805.02 | $805.02 | 527,700 |
| 10/22/2026 | $809.01 | $825.52 | $800.00 | $819.09 | $819.09 | 852,053 |
Analyst Price Targets
Based on 28 analysts covering REGN · as of Nov 5, 2026
Wall Street analysts forecast REGN stock price to rise 4.9% over the next 12 months.
Consensus
Buy4.18 / 5.00
Avg. Target
US$976.44
+4.9% Upside
Previously US$969.59 on Nov 4, 2026
Current Price
US$930.67
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
48.0%
Annualized
90-Day Vol
37.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
US$1112.62
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$987.75 | US$837.10 – US$1165.51 |
| 60 trading days | US$1048.33 | US$829.58 – US$1324.76 |
| 90 trading days | US$1112.62 | US$835.34 – US$1481.94 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Financials
- Revenue (TTM)
- $16.90B
- EBITDA
- $5.65B
- Profit Margin
- 28.51%
- ROE (TTM)
- 14.95%
- EPS (Diluted)
- 45.24
- Book Value
- 333.93
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About REGN.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| INM | InMed Pharmaceuticals Inc | $17.50 | +941.67% |
| OMH | Ohmyhome Limited Ordinary Shares | $15.55 | +432.53% |
| CRIS | Curis Inc | $1.11 | +56.34% |
| PMAX | Powell Max Limited Class A Ordinary Shares | $1.04 | +54.07% |
| RFAIR | RF Acquisition Corp II Right | $0.24 | +50.00% |
| CRCT | Cricut Inc | $8.88 | +48.74% |
| LYEL | Lyell Immunopharma Inc | $15.43 | +43.27% |
| GENVR | Gen Digital Inc. Contingent Value Rights | $4.03 | +42.40% |
REGN.US news timeline
15 articles covering REGN.US, most recent first
LatestRegeneron Posts Nearly Four Years of Libtayo Survival Data: What Investors Should Know
October 2026
- Regeneron’s Earnings Beat: What Investors Should Know
- Why Regeneron stock is rising today
- Why Regeneron stock is gaining today
- Why Regeneron stock is tanking today
- REGN vs ILMN: which stock is the better value?
- Why Regeneron stock is rising today
- Why Regeneron stock is gaining today
- Why Regeneron stock dropped yesterday
- Why Regeneron stock is tanking today
- Why Regeneron stock is sliding today